Acelyrin, Inc. (NASDAQ:SLRN) Insider Amar Murugan Sells 3,913 Shares

Acelyrin, Inc. (NASDAQ:SLRN) insider Amar Murugan sold 3,913 shares of the business’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $2.74, for a total transaction of $10,721.62. Following the completion of the sale, the insider now owns 121,587 shares in the company, valued at approximately $333,148.38. This trade represents a 3.12 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Acelyrin Stock Down 0.7 %

SLRN stock opened at $2.75 on Friday. The firm has a market cap of $275.90 million, a price-to-earnings ratio of -1.12 and a beta of 1.25. Acelyrin, Inc. has a twelve month low of $1.85 and a twelve month high of $7.86. The business’s fifty day simple moving average is $2.29 and its two-hundred day simple moving average is $3.82.

Acelyrin (NASDAQ:SLRN) last posted its earnings results on Wednesday, March 19th. The company reported ($0.79) EPS for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.07. Research analysts expect that Acelyrin, Inc. will post -2.53 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently commented on the company. HC Wainwright dropped their price target on Acelyrin from $8.00 to $6.00 and set a “neutral” rating for the company in a research report on Tuesday, January 7th. Citigroup dropped their target price on Acelyrin from $6.00 to $3.00 and set a “neutral” rating for the company in a report on Tuesday, January 7th. Finally, Wells Fargo & Company dropped their price objective on shares of Acelyrin from $15.00 to $13.00 and set an “overweight” rating for the company in a research note on Wednesday, December 11th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $9.60.

Institutional Trading of Acelyrin

Several large investors have recently bought and sold shares of SLRN. Intech Investment Management LLC acquired a new stake in shares of Acelyrin during the third quarter worth about $77,000. Charles Schwab Investment Management Inc. lifted its stake in Acelyrin by 81.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 609,678 shares of the company’s stock valued at $3,006,000 after acquiring an additional 273,604 shares during the period. Acuta Capital Partners LLC purchased a new stake in shares of Acelyrin in the 3rd quarter valued at $1,795,000. Martingale Asset Management L P acquired a new stake in shares of Acelyrin in the third quarter worth $485,000. Finally, Verition Fund Management LLC increased its stake in shares of Acelyrin by 55.1% in the third quarter. Verition Fund Management LLC now owns 110,115 shares of the company’s stock worth $543,000 after acquiring an additional 39,100 shares during the period. Hedge funds and other institutional investors own 87.31% of the company’s stock.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.